Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma

2020 ◽  
Author(s):  
Keyword(s):  
Retinitis Pigmentosa ◽  
Platelet Rich Plasma ◽  
Electromagnetic Stimulation

scholarly journals Management of Retinitis Pigmentosa via Platelet Rich Plasma or Combination with Electromagnetic Stimulation: Retrospective Analysis of One-year Results

2020 ◽  
Author(s):  
Umut Arslan ◽  
Emin Özmert
Keyword(s):  
Retinitis Pigmentosa ◽  
Retrospective Analysis ◽  
Platelet Rich Plasma ◽  
Progression Rate ◽  
Ellipsoid Zone ◽  
Electromagnetic Stimulation ◽  
Deviation Index ◽  
Autologous Platelet Rich Plasma ◽  
One Year ◽  
Autologous Platelet

Abstract Purpose To investigate whether the natural progression rate of retinitis pigmentosa can be decreased with subtenon autologous platelet rich plasma application alone or combination with retinal electromagnetic stimulation.Material and methods The study includes retrospective analysis of 60 retinitis pigmentosa patients. Patients constitute 3 groups with similar demographic characteristics. The combined management group consists of 20 retinitis pigmentosa patients (40 eyes) who received combined retinal electromagnetic stimulation and subtenon platelet rich plasma as Group1; The subtenon platelet rich plasma-only group consisted of 20 retinitis pigmentosa patients (40 eyes) as Group2; The natural course (control) group consists of 20 retinitis pigmentosa patients (40 eyes) who did not receive any treatment were classified as Group3. Horizontal and vertical ellipsoid zone width, fundus perimetry deviation index and best corrected visual acuity changes were compared within and between groups after one year follow up period.Results Horizontal ellipsoid zone percentage changes were detected +1 % in Group1, -2.85% in Group2, -9.36% in Group3 (Δp 1>2>3). Vertical ellipsoid zone percentage changes were detected +0.34 % in Group1, -3.05% in Group2, -9.09% in Group3 (Δp 1>2>3). Fundus perimetry deviation index percentage changes were detected +0.05% in Group1, -2.68% in Group2 and -8.78% in Group3 (Δp 1>2>3). Conclusion Platelet-rich plasma is a good source of growth factors, but its half-life is 4-6 months. Subtenon autologous platelet rich plasma might more effectively slow down photoreceptor loss when repeated as booster injections and combined with retinal electromagnetic stimulation.

Treatments Being Developed in Retinitis Pigmentosa

2021 ◽  
pp. 150-154
Keyword(s):  
Retinitis Pigmentosa ◽  
Retinal Pigment Epithelial ◽  
Vision Loss ◽  
Platelet Rich Plasma ◽  
Retinal Pigment ◽  
Retinal Prostheses ◽  
Pigment Epithelial ◽  
Recent Developments ◽  
Severe Vision Loss ◽  
Experimental Approaches

Recent developments in understanding the pathophysiology of retinitis pigmentosa (RP) have shown that there have been new hopes in the treatment of this disease which can cause severe vision loss. Proven therapy for RP-associated photoreceptor loss and retinal pigment epithelial damage has not yet been reported. New or experimental approaches for the treatment of RP include platelet-rich plasma, gene therapy, transplantation of fetal retinal cells or stem cells, and electronic retinal prostheses.

scholarly journals Stem Cell Surgery and Growth Factors in Retinitis Pigmentosa Patients: Pilot Study after Literature Review

Biomedicines ◽  
2019 ◽  
Vol 7 (4) ◽  
pp. 94 ◽  
Author(s):  
Paolo Giuseppe Limoli ◽  
Enzo Maria Vingolo ◽  
Celeste Limoli ◽  
Marcella Nebbioso
Keyword(s):  
Retinitis Pigmentosa ◽  
Platelet Rich Plasma ◽  
Functional Results ◽  
Point Of View ◽  
Foveal Thickness ◽  
Restoration Technique ◽  
Number Of Patients ◽  
Group A ◽  
Cell Surgery ◽  
Group B

To evaluate whether grafting of autologous mesenchymal cells, adipose-derived stem cells, and platelet-rich plasma into the supracoroideal space by surgical treatment with the Limoli retinal restoration technique (LRRT) can exert a beneficial effect in retinitis pigmentosa (RP) patients. Twenty-one eyes underwent surgery and were divided based on retinal foveal thickness (FT) ≤ 190 or > 190 µm into group A-FT and group B-FT, respectively. The specific LRRT triad was grafted in a deep scleral pocket above the choroid of each eye. At 6-month follow-up, group B showed a non-significant improvement in residual close-up visus and sensitivity at microperimetry compared to group A. After an in-depth review of molecular biology studies concerning degenerative phenomena underlying the etiopathogenesis of retinitis pigmentosa (RP), it was concluded that further research is needed on tapeto-retinal degenerations, both from a clinical and molecular point of view, to obtain better functional results. In particular, it is necessary to increase the number of patients, extend observation timeframes, and treat subjects in the presence of still trophic retinal tissue to allow adequate biochemical and functional catering.

Treatment of resistant chronic central serous chorioretinopathy via platelet-rich plasma with electromagnetic stimulation

2020 ◽  
Author(s):  
Umut Arslan ◽  
Emin Özmert
Keyword(s):  
Central Serous Chorioretinopathy ◽  
Platelet Rich Plasma ◽  
Chronic Central Serous Chorioretinopathy ◽  
Electromagnetic Stimulation ◽  
Micropulse Laser ◽  
Corrected Visual Acuity ◽  
Before And After ◽  
Subtenon Injection ◽  
The Mean ◽  
Best Corrected Visual Acuity

Background: To evaluate whether subtenon injection of platelet-rich plasma (PRP) with retinal electromagnetic stimulation (rEMS) is effective in therapy-resistant chronic central serous chorioretinopathy (CSCR). Design: Prospective, sequential. Materials & methods: The study included 22 eyes with resistant chronic CSCR. Cases receiving micropulse laser or additional photodynamic therapy, subtenon PRP, and subtenon PRP + rEMS were classified as times 1, 2 and 3, respectively. Results: At time 3, the mean best-corrected visual acuity was 85.7 and 97.0 letters before and after the procedures, respectively (p = 0.01). Submacular thickness improved by 17, 27 and 51% at times 1, 2 and 3 respectively. Conclusion: For treating resistant CSCR, subtenon PRP + rEMS should be considered as an effective and safe option. Trial Registration: ClinicalTrials.gov ID: NCT04224831

Sign in / Sign up

Export Citation Format

Share Document